A 12-month feasibility study of the RejuvenAir Metered Cryospray system revealed “clinically meaningful improvements” in multidimensional measures of cough, sputum production, breathlessness, QoL, and COPD Assessment Test, according to data presented by CSA Medical at ERS 2019.
The RejuvenAir System is an investigational cryosurgical device that applies spray liquid nitrogen to the central airways through a minimally invasive bronchoscopic procedure, according to CSA Medical. The system is designed to address the underlying causes of chronic bronchitis: the over-production of mucus and damaged cilia. The extreme-cold flash freezes damaged surface area lung cells which results in a rejuvenative healing process, the company reports.
According to the study results, 35 patients were enrolled in this safety and feasibility trial (NCT02483637) and all completed their treatments. The data presented showed clinically meaningful improvements in multidimensional measures of cough, sputum production, breathlessness, and Quality of Life (QoL), as measured by Saint George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT).
The one-year data showed superior scores in QoL measures versus pharmacologic standard of care regimens, according to CSA Medical. “Metered Cryospray appears to have a beneficial response with a decrease in cough and mucus production even in our patients who had optimized medical management. The overall improvement in breathing resulted in increased physical activity supporting the potential for RejuvenAir to measurably improve quality of life in chronic bronchitis patients,”said Dirk-Jan Slebos, MD, PhD, of the Department of Pulmonary Diseases, at the University Medical Center Groningen, The Netherlands.
The RejuvenAir System is under clinical investigation in the United States.